Search
VolitionRX Ltd
VNRXAdd to Watchlist
1.400USD
+0.020+1.47%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
555.14KMarket Cap
LossP/E TTM
More Details of VolitionRX Ltd Company
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VolitionRX Ltd Info
Ticker SymbolVNRX
Company nameVolitionRX Ltd
IPO dateFeb 06, 2015
CEOButera (Salvatore Thomas)
Number of employees85
Security typeOrdinary Share
Fiscal year-endFeb 06
Address1489 West Warm Springs Road
CityHENDERSON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code89014
Phone17024251561
Websitehttps://volition.com/
Ticker SymbolVNRX
IPO dateFeb 06, 2015
CEOButera (Salvatore Thomas)
Company Executives of VolitionRX Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
18.19K
-3.54%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
16.56K
-2.28%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
13.70K
-2.65%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
12.24K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
FAQs
Who are the top five shareholders of VolitionRX Ltd?
The top five shareholders of VolitionRX Ltd are: Mr. Guy Archibald Innes
How many institutions hold shares of VolitionRX Ltd (VNRX)?
As of 2026Q1, 66 institutions hold shares of VolitionRX Ltd, with a combined market value of approximately 1.13M, accounting for 13.93% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -209799.00.